The DOI matches its Crossref record.
Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952
Abstract
Purpose: This trial was conducted to determine whether high-dose fluorouracil (FU) given as a weekly 24-hour infusion is more active than bolus FU + leucovorin (LV), and whether high-dose infusional FU can be modulated by LV. Patients and Methods: A total of 497 patients with previously untreated metastatic colorectal cancer were randomly assigned to receive bolus FU 425 mg/m 2 intravenously + LV 20 mg/m 2 on days 1 to 5 and repeated on day 28 (FU + LV), or FU 2,600 mg/m 2 as a 24-hour infusion alone (FU 24h) or in combination with 500 mg/m 2 LV (FU 24h + LV)—all given weekly ×6 followed by a 2-week rest period. Survival was the major study end point. Results: With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU 24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU 24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P = .724). Progression-free survival (PFS) was significantly longer for FU 24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU 24h, 4.1 months [95% CI, 3.4 to 5.0]; FU 24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P = .029). The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU 24h, and FU 24h + LV, respectively (not significant). Occurrence of grade 3 and 4 diarrhea was higher in the FU 24h + LV arm (22%) compared with the FU 24h (6%) or FU + LV (9%) arms; however, stomatitis (11% in FU + LV v 3% in FU 24h v 5% in FU 24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm. Global quality of life did not differ within the three arms. Conclusion: Neither FU 24h + LV nor FU 24h prolong survival, relative to bolus FU + LV. Leucovorin increases PFS if added to FU 24h, but increases toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525
Self-citationSystemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 504
Österlund, P., Ruotsalainen, T., Korpela, R., Saxelin, M., Ollus, A., Valta, P., Kouri, M., Elomaa, I., & Joensuu, H. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603990 · Cited by 405
(2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.104 · Cited by 389
Drug interactions in cancer therapy
Scripture, C. D., & Figg, W. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1887 · Cited by 366
Köhne, C.-H., van Cutsem, E., Wils, J., Bokemeyer, C., El-Serafi, M., Lutz, M. P., Lorenz, M., Reichardt, P., Rückle-Lanz, H., Frickhofen, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.546 · Cited by 331
Self-citationSystemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
Kelly, H., & Goldberg, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.749 · Cited by 316
Folprecht, G., Cunningham, D., Ross, P., Glimelius, B., Di Costanzo, F., Wils, J., Scheithauer, W., Rougier, P., Aranda, E., Hecker, H., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh344 · Cited by 257
Self-citationTherapy for Metastatic Colorectal Cancer
Goldberg, R. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-9-981 · Cited by 78
Metadata
- Authors
- Köhne, C.-H., Wils, J., Lorenz, M., Schöffski, P., Voigtmann, R., Bokemeyer, C., Lutz, M., Kleeberg, U., Ridwelski, K., Souchon, R., El-Serafi, M., Weiss, U., Burkhard, O., Rückle, H., Lichinitser, M., Langenbuch, T., Scheithauer, W., Baron, B., Couvreur, M. L., & Schmoll, H. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-10-15
- Volume
- 21
- Issue
- 20
- Pages
- 3721-3728
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2115366398
- Cited by
- 160
- References
- 0
- FWCI
- 9.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.